Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Lupin: FIRST to win Canadian approval for generic version of Inderal-LA capsules

      Lupin: FIRST to win Canadian approval for generic version of Inderal-LA capsules

      Farhat Nasim14 Sept 2019 9:45 AM IST
      Lupin is the first generic company to receive approval for generic Inderal-LA capsules for the Canadian market and the product will be manufactured at...
      Cutting Debts: Apollo Hospitals sells stake worth Rs 720 crore

      Cutting Debts: Apollo Hospitals sells stake worth Rs 720 crore

      Farhat Nasim12 Sept 2019 5:03 PM IST
      Apollo promoters' are being guided by the Citigroup and HDFC Bank on the current stake sale. The 5 million shares or 3.6% stake in the company will be...
      Oops! Salmonella bacteria found in MDH sambar masala, USFDA orders recall

      Oops! Salmonella bacteria found in MDH sambar masala, USFDA orders recall

      Farhat Nasim12 Sept 2019 3:52 PM IST
      "The MDH sambhar masala recall was initiated after it was discovered by the USFDA that the salmonella contaminated products were distributed," the...
      Price cap of Orthopaedic Knee Implants led to boosted sales, says NPPA

      Price cap of Orthopaedic Knee Implants led to boosted sales, says NPPA

      Farhat Nasim11 Sept 2019 6:42 PM IST
      New Delhi: The apex drug price regulator, the National Pharmaceutical Pricing Authority (NPPA) has apprised about the positive impact of capping...
      BAN: Private Sectors wont be allowed to sell Detox Drug Buprenorphine in Punjab

      BAN: Private Sectors wont be allowed to sell Detox Drug Buprenorphine in Punjab

      Farhat Nasim10 Sept 2019 4:11 PM IST
      Apart from this, the Government intends to allow psychiatric clinics to dispense buprenorphine and naloxone. It is also in the process of framing...
      A Step By Step Guide On How To Claim Term Life Insurance

      A Step By Step Guide On How To Claim Term Life Insurance

      Farhat Nasim10 Sept 2019 3:16 PM IST
      New Delhi: Arup, aged 50 years, died of a sudden cardiac arrest, and is survived by his wife and son. Arup’s wife, Vidya is an educated homemaker, and...
      Pharma, Bio-Pharma manufacturing units to follow Apprentices Act: CDSCO issues advisory

      Pharma, Bio-Pharma manufacturing units to follow Apprentices Act: CDSCO issues advisory

      Farhat Nasim8 Sept 2019 4:34 PM IST
      New Delhi: Through a recent advisory, the apex drug regulatory body- Central Drugs Standard Control Organization (CDSCO) has directed all...
      Fight for Vildagliptin: Natco goes to court against Novartis

      Fight for Vildagliptin: Natco goes to court against Novartis

      Farhat Nasim7 Sept 2019 4:32 PM IST
      Mumbai: Throwing an indirect challenge at patent holder Novartis, drugmaker Natco Pharma has submitted a fresh application in a Hyderabad court...
      Protect Your Loved Ones with a Term Plan that’s Smart

      Protect Your Loved Ones with a Term Plan that’s Smart

      Farhat Nasim6 Sept 2019 5:18 PM IST
      New Delhi: Life is unpredictable, and not everything is in your hand. It is wise that you remain prepared to face adversities that may come your way....
      Heres What it Takes to Pursue B Pharma in India

      Here's What it Takes to Pursue B Pharma in India

      Farhat Nasim6 Sept 2019 5:18 PM IST
      New Delhi: The high demand for health care in India has made it an ever-growing industry. This increasing demand has turned the healthcare industry...
      Landmark Trial for Dapagliflozin: AstraZeneca diabetes drug Forxiga shows benefits in patients with heart failure

      Landmark Trial for Dapagliflozin: AstraZeneca diabetes drug Forxiga shows benefits in patients with heart failure

      Farhat Nasim6 Sept 2019 9:17 AM IST
      Dapagliflozin(Forxiga) is currently available and indicated for type 2 diabetes in India and not yet approved for treatment for heart failure in...
      Payment of fees in Bharatkosh through Sugam portal: CDSCO issues notice

      Payment of fees in Bharatkosh through Sugam portal: CDSCO issues notice

      Farhat Nasim5 Sept 2019 5:26 PM IST
      In order to facilitate the payment of fees by the stakeholders, it has been decided by the Directorate that once the fees are debited from the account...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok